Comparative Pharmacology
Head-to-head clinical analysis: DACARBAZINE versus URACIL MUSTARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DACARBAZINE versus URACIL MUSTARD.
DACARBAZINE vs URACIL MUSTARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent; inhibits DNA and RNA synthesis by forming covalent bonds with DNA, leading to cross-linking and strand breaks. Also inhibits purine synthesis and has some activity as a methylating agent.
Uracil mustard is a nitrogen mustard alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death.
2.4-4.5 mg/kg IV daily for 10 days every 28 days; or 250 mg/m2 IV daily for 5 days every 21 days; or 375-450 mg/m2 IV single dose every 21-28 days.
1 mg orally daily for 3 weeks, then 1 mg daily every 4 weeks, or 0.15 mg/kg orally once weekly.
None Documented
None Documented
Terminal half-life: 5 hours (range 3-8 h) after IV administration; biphasic decay with initial half-life ~19 min.
Clinical Note
moderateDacarbazine + Digoxin
"Dacarbazine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateUracil mustard + Digoxin
"Uracil mustard may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDacarbazine + Digitoxin
"Dacarbazine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateUracil mustard + Digitoxin
"Uracil mustard may decrease the cardiotoxic activities of Digitoxin."
Terminal half-life approximately 6–8 hours in patients with normal renal function; may be prolonged with renal impairment
Renal: 40-50% unchanged; hepatic: 30-50% as metabolites (primarily 5-aminoimidazole-4-carboxamide); <10% fecal.
Primarily renal (56-80% as unchanged drug and metabolites); minor fecal (10%)
Category D/X
Category C
Alkylating Agent
Alkylating Agent